This was the ADR's second consecutive day of gains. AstraZeneca PLC ADR closed 14.07% below its 52-week high of $87.68, which ...

The intervention being tested involves the use of Baxdrostat and Dapagliflozin, both administered as tablets. Baxdrostat is being evaluated for its potential to enhance the cardiovascular benefits of ...

The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

AstraZeneca PLC (NASDAQ:AZN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. AstraZeneca PLC (NASDAQ:AZN) and ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly transferring manufacturing” across the Atlantic.

AstraZeneca CEO Pascal Soriot told Italy’s La Repubblica at the time that its agreement with the EU was “not a contractual commitment. It’s a best effort,” referring to language used in ...